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Dissection of a QTL Locus on Mouse Proximal Chromosome 5 
that Modulates Intraocular Pressure (IOP) leads to Identification 
of a Potential New Drug Target for Glaucoma
Shankar Swaminathan1, Hong Lu1, 2, Janey L. Wiggs3, Robert 
W. Williams2, Lu Lu2, Monica M. Jablonski1, 2. 1Ophthalmology, 
Hamilton Eye Institute, The University of Tennessee Health Science 
Center, Memphis, TN; 2Anatomy & Neurobiology, The University of 
Tennessee Health Science Center, Memphis, TN; 3Ophthalmology, 
Harvard Medical School, Massachusetts Eye and Ear Infirmary, 
Boston, MA.
Purpose: Current IOP lowering therapies are used on a trial and error 
basis without a pharmacogenomic rationale, leading to variability 
in drug effect. Within our large high-throughput gene screening, we 
identify genetic modifiers of IOP using the enlarged BXD glaucoma 
murine reference panel in combination with human GWAS glaucoma 
cohorts. Our objective in the study was to identify new gene loci 
modulating IOP using systems genetics and design new drug targets 
for personalized glaucoma therapy.
Methods: We acquired IOP measurements for parents and 80 
progeny BXD lines at 1–2, 3–5, 6–9, 10–13 and >13 months of 
age, using a TONOLAB. Conventional arrays and RNA-seq data 
were used to estimate gene expression from eyes of parents and 
progeny. IOP datasets were mapped using GeneNetwork (www.
genenetwork.org). Candidate genes for high IOP/ primary open angle 
glaucoma (POAG) were nominated using the following criteria: (1) 
genes are located within confidence intervals of QTLs; (2) genes 
have coding differences segregating among progeny; (3) genes are 
expressed in the eye, and are associated with cis-expression QTL 
(eQTL); (4) expression of transcripts covary with IOP; (5) genes 
have a plausible biological link to IOP and glaucoma; (6) genes are 
close to linkage peaks in the GLAUGEN and NEIGHBOR human 
POAG GWAS studies; and (7) genes are druggable. Subsequently, 
a druggable gene drug target and a small molecule drug were 
selected for further studies. The IOP lowering effect on high and low 
expresser BXD strains of the selected gene was studied (n=6) and the 
pharmacodynamic profile computed.
Results: IOP varied from 9.3±0.8 to 21.8±1.7 mmHg across BXDs. 
We identify a robust eQTL on proximal Chr 5 in BXD mice strains 
aged 10–13 mo. Within this QTL, candidates were nominated and the 
best SNP in each candidate were identified using human data from 
the GLAUGEN/NEIGHBOR GWAS data. Within the candidates, 
we identified a druggable gene target (a cation channel; p-value= 
0.007526) that regulated ion transport in the eye. A single topical 
dose of the cation channel blocker reduced IOP by >4mmHg (>20%) 
in high BXD expressers from baseline within 3 h and returned to 
baseline after 6 h.
Conclusions: We have identified potential candidate genes that 
modulate IOP and further evaluated the suitability of a druggable 
gene target for personalized POAG therapy.
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Ocular hypotensive effects of the KATP channel opener 
cromakalim in murine and human experimental model systems
Uttio Roy Chowdhury, Cindy K. Bahler, Bradley H. Holman, Michael 
P. Fautsch. Ophthalmology, Mayo Clinic, Rochester, MN.
Purpose: Studies from our laboratory have shown that the KATP 
channel opener diazoxide lowers intraocular pressure (IOP) by 
activating the SUR2B/Kir6.2 subunit containing channels. In this 
study, we evaluated the IOP lowering ability of the broad spectrum 
KATP channel opener cromakalim (CKL) which activates both 
SUR2B/Kir6.2 and SUR2A/Kir6.2 subunit containing channels. 
Efficacy of combination therapy with CKL and latanoprost free acid 
(LFA) was also evaluated.
Methods: Human anterior segment pairs (n=10, mean age 72.5±15.1, 
range 52 to 88 years) were placed in perfusion organ culture and 
treated with CKL (0.02 mM, 0.2 mM, and 2 mM) or vehicle (DMSO). 
In vivo IOP-lowering effects of topically administered CKL (5 
mM in 10% cremophor EL), either alone or in combination with 
LFA (0.005% in PBS, n=10), was evaluated in wild type C57BL/6 
mice using a handheld rebound tonometer. Subunit specificity of 
CKL was studied in Kir6.2
(-/-) mice (n=10). Tissue morphology of 
all eyes treated with CKL, LFA and respective vehicles was imaged 
by transmission electron microscopy and evaluated by at least two 
independent masked observers.
Results: Cromakalim (2 mM) increased outflow facility in human 
anterior segments compared to baseline (0.13±0.02 to 0.20±0.04 
ml/min/mmHg, n=10, P<0.001). Outflow facility was unchanged 
in the vehicle treated segments (0.18±0.06 to 0.17±0.05 ml/min/
mmHg, n=10, P=0.9). No change in outflow facility was observed 
with cromakalim added at 0.02 or 0.2 mM. In vivo, mouse eyes 
treated with CKL alone showed a 20.3% reduction in IOP compared 
to control (13.63±0.16 to 17.1±0.35 mmHg, n=5, P<0.001). When 
CKL was combined with LFA, IOP decreased by an additional 
71% compared to mice eyes treated with CKL alone (n=10, 
P<0.001). Treatment of Kir6.2
(-/-) mice with CKL did not show any 
reduction in IOP (16.09±0.26 mmHg to 16.09±0.29 mmHg, n=10, 
P>0.05). Histologic analysis of treated and control eyes showed 
no major disruptions of the inner and outer wall of Schlemm’s 
canal, comparable cell numbers, and extracellular matrix integrity 
throughout the trabecular meshwork.
Conclusions: The KATP channel opener CKL is a potent ocular 
hypotensive agent that specifically acts through the Kir6.2 subunit 
containing KATP channels. The mechanism of action of CKL is distinct 
to that of LFA. The KATP channel opener CKL has potential as an 
ocular hypotensive agent either alone or in combination with LFA.
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Preclinical Evaluation of ENV515 (travoprost) Intracameral 
Implant - Clinical Candidate for Treatment of Glaucoma 
Targeting Six-Month Duration of Action
Tomas Navratil1, Andres Garcia1, Janet Tully1, Benjamin Maynor1, 
Iqbal Ike K. Ahmed4, Donald L. Budenz5, Richard A. Lewis2, Steven 
L. Mansberger3, Brian C. Gilger6, Benjamin R. Yerxa1. 1Envisia 
Therapeutics, Research Triangle Park, NC; 2Sacramento Eye 
Consultants, Sacramento, CA; 3Devers Eye Institute, Portland, OR; 
4University of Toronto, Toronto, ON, Canada; 5University of North 
Carolina, Chapel Hill, NC; 6North Carolina State University, Raleigh, 
NC.
Purpose: Prostaglandin analogues (PGA) are the most prescribed 
class of therapies for glaucoma in the US but possess several 
shortcomings: low adherence, hyperemia, and fluctuation in ocular 
drug levels and intraocular pressure (IOP). The purpose of this work 
was to evaluate the efficacy, duration of action, and safety/tolerability 
of the ENV515 (travoprost) Intracameral Implant experimental 
therapy prior to further preclinical and clinical development. ENV515 
is a biodegradable polymer drug delivery system using an extended 
release formulation of the PGA travoprost. ENV515 is being 
developed with the aim to address the shortcomings of the topical 
PGA therapies.
Methods: We used PRINT® technology to fabricate ENV515 
to fit the anatomy of the human iridocorneal angle and allow 
administration via acceptably-sized needle. We used hypertensive and 
normotensive Beagle dogs using a modified McDonald-Shadduck 
scale to evaluate safety and tolerability over a period of 24 weeks 
in vivo. The in vivo location of the implant was imaged via anterior 
chamber OCT and Gonioscopy exams. IOP was evaluated in non-
sedated animals.
Results: In vitro, the extended release of travoprost from ENV515 
occurred over a period of 180 days. The implant administrations were 
conducted in Beagle dogs by intracameral injections via a custom 
injector and resulted in 100% success rate for implant delivery. 
Gonioscopy and anterior chamber OCT imaging showed stability 
without movement in the iridocorneal angle in hypertensive Beagle 
dogs (Figures 1 and 2). The baseline IOP in hypertensive Beagle 
dog study was 23.4±1.0 mmHg (mean±SEM, n=6 eyes). The mean 
decrease in intraocular pressure was 7.2±0.5 mmHg or 30±2% 
change from baseline IOP over 24 week treatment period (p<0.001). 
Only minor and transient ocular irritation occurred due to the 
insertion procedure. Notably, there was lower incidence of hyperemia 
compared to topical TRAVATAN Z. Similar outcomes were observed 
in a replicatory study in normotensive Beagle dogs.
Conclusions: ENV515 demonstrated robust, sustained IOP-lowering 
effect for 24 weeks following single implantation via intracameral 
injection with acceptable safety and tolerability in hypertensive 
and normotensive Beagle dogs. ENV515 preclinical safety and 
tolerability profile supports advancing ENV515 into clinical studies 
in glaucoma patients.
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Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024% 
Compared With Timolol Maleate Ophthalmic Solution 0.5% 
in Lowering IOP over 24 hours in Subjects With Open Angle 
Glaucoma or Ocular Hypertension (CONSTELLATION)
John H. Liu1, Jason L. Vittitow2, Quintus Ngumah2, Robert N. 
Weinreb1. 1Dept of Ophthalmology and Hamilton Glaucoma Center, 
Univ of California, San Diego, La Jolla, CA; 2Bausch & Lomb, 
Madison, NJ.
Purpose: To compare the effect of latanoprostene bunod (LBN) 
0.024% QD with timolol maleate 0.5% BID in reducing 24-hour 
intraocular pressure (IOP) in subjects with open angle glaucoma 
(OAG) or ocular hypertension (OHT).
Methods: This was a randomized, single-center, open-label, 2-period, 
8-week study with crossover at 4 weeks. Twenty subjects (43–82 
years) with a baseline IOP at least 22 mmHg in at least 1 eye and less 
than 36 mmHg in both eyes and a diagnosis of OAG or OHT were 
included. Subjects were housed in a sleep laboratory for 24 hours and 
a baseline IOP profile was created. IOP of both eyes was measured 
with a pneumatonometer every two hours in the sitting and supine 
positions from 8AM to 10PM, and in the supine position only from 
12AM to 6AM. During the first period of the study subjects were 
randomized 1:1 to either of 2 treatment sequences: LBN 0.024% 
instilled in both eyes at 8PM or timolol maleate 0.5% instilled twice 
a day at 8AM and 8PM. After four weeks of treatment, subjects 
were housed in the sleep laboratory for a second 24 hour period IOP 
measurement. At the end of the 24 hours, subjects were crossed over 
to receive the comparator treatment, which initiated period 2. After 
four weeks of the period 2 treatment, subjects were housed in the 
sleep laboratory for a third 24 hour IOP measurement. The mean IOP 
from both periods for the 2 treatment groups (LBN 0.024% QD and 
timolol maleate 0.5% BID) were compared using a Mixed Model 
Repeated Measures analysis of variance (ANOVA) model, during the 
diurnal, nocturnal, and 24 hour periods.
Results: Mean change from baseline in IOP (mmHg) was 3.9±0.28 
for latanoprostene bunod treated eyes and 2.4±0.29 for timolol treated 
eyes during the diurnal period; 2.75 ± 0.45 for latanoprostene bunod 
and 0.2±0.46 for timolol during the nocturnal period; and 3.5 ± 0.24 
for latanoprostene bunod and 1.7±0.25 for timolol during the entire 
24 hour period.
Conclusions: In this group of open angle glaucoma/ocular 
hypertensive patients, LBN 0.024% was shown to be superior to 
timolol with regard to IOP lowering during the entire 24 hour period 
measured (p<0.05), suggesting that treatment with LBN 0.024% may 
provide more effective and better sustained diurnal and nocturnal IOP 
reduction.
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Observation periods of 1 year for clinical trials of neuroprotective 
agents in glaucoma are feasible
David F. Garway-Heath1, Haogang Zhu1, 2, David P. Crabb2. 1Institute 
of Ophthalmology, University College London, London, United 
Kingdom; 2Optometry and Visual Science, City University London, 
London, United Kingdom.
Purpose: Before the United Kingdom Glaucoma Treatment 
Study (UKGTS), a placebo-controlled treatment trial for manifest 
glaucoma, clinical trials in glaucoma with a visual field (VF) outcome 
typically had observation periods of 5 years or longer. The UKGTS 
reported a significant outcome with a 2-year observation period, with 
the difference between treatment arms evident after only 12 months. 
The UKGTS was designed to maximize the precision of estimates of 
progression rate (speed). In this study, the UKGTS data were used as 
the basis for modelling a trial of neuroprotection.
Methods: The assumed study design is a placebo-controlled trial of a 
neuroprotective agent, with all patients taking latanoprost in addition. 
The rates of progression from the eye with the worst VF loss at 
baseline in the latanoprost-treated arm of the UKGTS, with at least 
6 months of follow-up, were used for modelling. For patients with 
less than 12 months follow-up, the rate for the available series was 
used. The modelling of the UKGTS VF data identified the outcome 
with greatest power to separate treatment groups as the mean rate of 
loss at the 10 fastest deteriorating locations in each eye. Progression 
rates were determined using a technique called ‘ANSWERS’ (Zhu 
et al. PLoS ONE: in press) and pointwise ordinary least squares 
linear regression (PLR). ANSWERS is a regression technique which 
accounts for the increasing variability with declining VF sensitivity. 
The study sample size was calculated for treatment effects of a 10%, 
20% and 30% reduction in progression rate in latanoprost-treated 
eyes over a 12-month period for power=0.90 and two-sided P=0.05. 
Sample sizes for pilot studies (power=0.80 and P=0.10) were also 
calculated.
Results: For a modest treatment effect of 20% rate reduction, 
888 patients are needed (Table). For a more clinically significant 
treatment effect of 30% rate reduction, 390 patients are needed for an 
observation period of 12 months. For a pilot study, treatment effect of 
30% rate reduction, 230 patients are required.
Conclusions: A clinical trial, with a VF outcome and an observation 
period of only 12 months, for a neuroprotective agent in patients on 
IOP-lowering treatment for glaucoma is feasible.
Sample size required to identify a progression rate reduction of 10%, 
20% and 30% in latanoprost-treated eyes
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The Relationship between Intraocular Pressure and Rates of 
Estimated Retinal Ganglion Cell Loss in Glaucoma.
Amir Marvasti1, 2, Andrew J. Tatham1, Linda M. Zangwill1, Robert 
N. Weinreb1, Felipe A. Medeiros1. 1Hamilton Glaucoma Center, 
Department of Ophthalmology, University of California, San Diego, 
San Diego, CA; 2Boston University School of Medicine, Boston, 
MA.
Purpose: To evaluate the influence of mean intraocular pressure 
(IOP) during follow up on rates of estimated retinal ganglion cell 
(RGC) loss in glaucoma.
Methods: 270 eyes of 178 subjects with glaucoma and suspected 
glaucoma were followed for mean ± SD of 6.3 ± 2.7 (range: 2.1 to 
11.0) years, with an average of 9 ± 3 (range: 5 to 17) visits duri
Results: At baseline, the average SAP mean deviation (MD) was -2.4 
± 3.8 dB and average estimated RGC count was 776,077 ± 230,127 
cells. Mean IOP during follow up was 16.8 ± 4.4 mmHg (range: 4.8 
to 27.6). Average CCT was 554.1 ± 36.7 mm. There was a significant 
nonlinear relationship between the estimated rate of RGC loss and 
mean IOP during follow up with higher IOP associated with a higher 
rate of RGC loss. In a multivariable model including mean IOP, 
(mean IOP)^2, CCT, an interaction term CCT*mean IOP, and age at 
baseline, all variables were significantly associated with rate of RGC 
loss (P<0.05). Eyes with a mean IOP of 10 mmHg during follow up 
had estimated RGC losses close to the expected age-related loss of 
6,944 cells per year. In contrast, mean IOPs of 16 mmHg, 22 mmHg, 
and 28 mmHg were associated with losses of 9,869 cells, 17,794 
cells, and 30,718 cells per year, respectively (Figure 1).
Conclusions: Higher mean IOP during follow up is associated 
with greater rates of estimated RGC loss in eyes with glaucoma or 
suspected glaucoma.
Modeled relationship between estimated rate of RGC loss and mean 
IOP during follow up.
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Evaluation of the Retinal Hemodynamics in Patients with 
Primary Open Angle Glaucoma and Differing Nocturnal Blood 
Pressure Profiles
Firdaus Yusof1, 2, Richard Cheng3, Nadia Espahbodi3, Lee-Anne 
Khuu3, Yvonne M. Buys3, Graham E. Trope3, Christopher Hudson1, 
3, John G. Flanagan1, 3. 1School of Optometry and Vision Science, 
University of Waterloo, Waterloo, ON, Canada; 2Department of 
Optometry and Visual Science, International Islamic University of 
Malaysia, Kuantan, Malaysia; 3Department of Ophthalmology and 
Vision Sciences, University of Toronto, Toronto, ON, Canada.
Purpose: To evaluate the retinal hemodynamic response to normoxic 
hypercapnia among patients with primary open angle glaucoma 
(POAG) and differing nocturnal blood pressure (NBP) profiles, using 
Doppler spectral-domain optical coherence tomography (SD-OCT).
Methods: Doppler SD-OCT retinal blood flow (RBF) measurement 
was acquired using the circum-papillary double circular scan protocol 
of the RTVue system (Optovue Inc., Freemont, CA). The sample 
consisted of 17 healthy controls (group mean age 62±7 years; group 
mean NBP dip 14±8%); 17 POAG with normal NBP dip (age 66±9 
years; NBP dip 11±5%), termed “dippers”; and 16 POAG with high 
NBP dip (age 64±7 years; NBP dip 24±5%), “over-dippers”. The 
NBP dip magnitude was calculated by taking the difference between 
mean arterial pressure (MAP) during the day and night while awake 
and asleep, respectively. Automated gas blender (RespiractTM, 
Thornhill Research Inc., Toronto) was used to stably provoke 
normoxic hypercapnia (15% increase in the end-tidal carbon dioxide 
partial pressure relative to homeostatic baseline). Six Doppler SD-
OCT RBF scans were acquired, during baseline and also during 
normoxic hypercapnia. RBF parameters were calculated and ANOVA 
was used to compare values between groups (p<0.05).
Results: Total RBF at baseline was significantly different between 
the groups with controls being the highest (37.1±4.4mL/min), and 
over-dippers the lowest (29.6±9.0mL/min). Venous area showed 
significant differences at baseline between the groups with the lowest 
value in the over-dipper group, and the highest in the control group 
(39.9±7.0(x10-3)mm, and 46.6±6.6x(10-3)mm, respectively). Velocity 
was not significantly different between groups (p=0.27) at baseline. 
Breathing normoxic hypercapnia provoked an increase in flow that 
was significantly lower in the over-dipper group (1.0±8.6mL/min) 
and highest in the controls (8.2±10.8mL/min). Change in velocity was 
significantly different (p=0.02) between the groups, being highest in 
the control group (2.4±3.3mm/s) and lowest in the over-dipper group 
(-0.6±3.1mm/s). Venous area change was not significantly different 
between groups.
Conclusions: Patients with POAG who exhibited an exaggerated 
nocturnal reduction in MAP also demonstrated lower baseline 
RBF values and an impeded retinal vascular response to normoxic 
hypercapnia, indicating greater vascular dysregulation in this group.
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